Report to the Board. Budget 334 Million TLDirect report, team of 13 Sales, Marketing Manager, Store Manager and their respective staff approximately of 663 employees- (Sanset 565 – Montero Baby Nutrition 98).employees. Montero team Achievement• Strategized and implemented marketing campaign focused on new market segments. Exceeded all quarterly goals by 128 %. Efforts resulted in revenue growth of TL 26 566 000 YOY.• Created the company strategies and plans from zero, actively took a role to select the product range, organized the agreement from Spain where the products are produced.• All launch new products process planned and realized for Evolvia AR, Evolvia AC, Evolvia Premature. Also, after the launch, controlled if the products are good enough related to the product plans.• From pharmacy sales, Evolvia Nutripro sales result increased from 289 976 chest to 525. 502 chest, chest grow % 87, revenue grow % 81,2 and the final earn was 14.286 000. (According to IMS 2016 MAT data, the product has been ranked 3.) From supermarkets sales well known names as Migros, C4, Ebebek, Joker, revenue 12.280.000 TL, total revenue 26 566 000 TL.• In 2016 Evolvia AR, AC and Premature products have been launched to the market by the end of the first year, market share realized % 10. IMS 12/ 2015• Considering the prescription share of the products, in second year, from prescription reached from 236.000 to 520. 665 pack, as % 38,36 result the product became the leader among the other competitors. IMS/ 2015

Reports board of the Toksöz Group. Budget 281 Million TLDirect report, team of 14 sales and Marketing managers and their respective staff approximately 360 employees. Products as:Lansor(Proton Pump İnhibitors) Majezik, Nimes,(Analgesic), Nimes Combo and Kenfix ( Muscle Relaxing), Macrol, Sefsidal(Antibiotic), Zolax(Antifungal), Selectra(Antidepressant) Cedrina, Ignis, Oferta( Antipsychotics), Symra( Pregabalin), Neruda(Gabapentin) , Doenza( Donapezil), Netrolex(Levitresetam) Achievement• Lansor (Lansapazol) reached up 100 million TL revenue is ranked 9 product , Majezik (Florbiburufen) (Analgesic, Anti-inflammatory) reached up to 46 million TL revenue and ranked as 44, Macrol ( Macrolide), in antibiotic market reached up 35 million revenue and ranked 77 product in total Pharma market. (IMS 12/ 2015)• Launched six new product for CNS and Pharma markets, their total revenue 46 million (Gabapentin Market Neruda 16 M, Pregabalin market Symra 7,2M, Antipsychotic market Aripiprazol İgnis 7,8M, Analgesic-Muscle Relaxing market Nimes Combo 4.9M, Muscle Relaxing market Kenfix Tiyokolşikosid 3M, Antiepileptic market Levitresetam Netrolex 3M.• Developed and executed strategies that focused on client requirements and maximized sales. Mentored team members to exceed established goals and excel within the company.• Demonstrated excellence in sales leadership and evaluate the team based on their performance regularly. • By considering the project called S1E, in the following two years, pharmacy sales success rate increase from % 8 to % 36.

Reports The General ManagerProducts as ; New cell base therapy products (MACI), Adhesion barrier (Seprafilm), Burn cell therapy (Epicel), and Hyaluronic acid market (Synvisc, Jonexa). Achievement• Enabled the application of the marketing plans which he had prepared by adapting the global plans for the country during the Medico marketing education, strategy and workshop meetings he attended which were organized by the Genzyme Europe BUM and Global brand directors.• Conducted all the process comprising the marketing plans for launching Jonexa in the OA market in 2010, strategy localization, advisory board and KOL meetings and preparation of the study cards all by himself. • By organizing meetings for the structuring of the Cellular Treatment, which is a new treatment application in Turkey and to which the Ministry and the Sports Injuries Committee participated, he played an active role in the formation of the MACI procedures and accomplishment of the refund periods.• By regularly controlling the activities of the distributors in terms of convenience to the strategies of Genzyme and by determining the development fields, he realized the sales objectives by helping the medical marketing and sales trainings to be organized. • Analyzed the market for regional and brick potentials and took the right photo for the company strategies, organized monthly meetings with the distributors, sales and marketing team.• Analyzed monthly IMS and the regional data and discussion of the ongoing business plan and action plans . Conducted literature searches, physician interviews, focus groups and advisory boards necessary to understand and define potential of new market opportunities.• Participated in the local, national and international conferences to meet the opinion leaders and the other MDs, to promote the products and to develop personal relations.• 46% sales growth in YTD/10/2010 versus YTD/10/2009.

Reports to the board, Budget responsibility of 315 million TL, Direct Reports as sale staff of 7 FFM, 52 DSM, 631 Reps( 3 lines are working pharmacies and physicians. 1 line is working special physicians, 1 line is working pharmacies generic and OTC drug.),Products as:As original brands right; 5 products in Antihypertensive Market (Vasoksen Nebivaolol),Hipersar, Hipersar Plus (Olmesartan) ,Zopretec Zoprotec Plus (Zefonopril), 1 product in Ant migraine market(Migrex,Frovatriptan), 1 product in Analgesic Market (Aravels Dexketeprofen), 1product in Antispasmodic (Spasmomen Otilunyum bromüre) Market, 1 product in Antiviral Market( Zostex Brivüdine), 1 product in Topical Analgesics(Fast Jel).Achievement• Considering a 40% growth in TL compared to the previous year, with the successful team management in 2007, provided the company to be the 3rd largest pharmaceutical company within top 20 firms in IMS ratings of 2007. (IMS 2007 sale worth 286.000.000 TL)• In terms of box sales in 2007, provided to be 3rd in multinational companies rating and 4th in all firms with 74.194.440 boxes. (IMS 2007)• In 2006, after taking Turkey responsibility of Olmesartan molecule, the co-marketing of which is made together with Pfizer in antihypertensive market, provided it to be in front of Pfizer molecule for every time and in 2nd place in 2008 for its own market. (Market share of 13.62 according to IMS September MAT 2008 data). By reaching 2.326.000 boxes from 1.773.000 boxes in 2 years with the products in antihypertensive market (Vasoxen. Zoprotec, Hipersar), it took the 2nd place in TL market with 40.170.000 TL.

Reports to Sales Director. Budget 45 million TLThe area of responsibility: Central Anatolia Ankara(3), Kayseri, Aegean(3), Bursa(2), Marmara(3) Regions. (12 DSM 96 REP)In addition to these responsibilities have gained experience by assuming an active role in terms of annual and periodical marketing plans and pursuing of the responsible products.Products as:Anti-depressive (Prozac Fluoksetin ), Antiulcer (Axid Nizatidin), Antibiotics( Ceclor Sefaclor, Lorabid Loracarbef) and Erectile Dysfunction (Cialis Sildenafil)Markets.